NasdaqGS:STOKBiotechs
Stoke Therapeutics (STOK): Reassessing Valuation After New Zorevunersen Data at the 2025 AES Meeting
Stoke Therapeutics (STOK) just delivered another data update on zorevunersen at the 2025 American Epilepsy Society meeting, and it matters because it strengthens the long term disease modification story in Dravet syndrome.
See our latest analysis for Stoke Therapeutics.
The latest AES data drop lands after a big run, with the 30 day share price return of 35.04 percent and year to date share price return of 173.91 percent supporting a strong 1 year total shareholder return of 124.35 percent...